12931_2021_1863_MOESM1_ESM.docx (436.29 kB)
Additional file 1 of Dual inhibition of αvβ6 and αvβ1 reduces fibrogenesis in lung tissue explants from patients with IPF
journal contribution
posted on 2021-10-20, 03:27 authored by Martin L. Decaris, Johanna R. Schaub, Chun Chen, Jacob Cha, Gail G. Lee, Megi Rexhepaj, Steve S. Ho, Vikram Rao, Megan M. Marlow, Prerna Kotak, Erine H. Budi, Lisa Hooi, Jianfeng Wu, Marina Fridlib, Shamra P. Martin, Shaoyi Huang, Ming Chen, Manuel Muñoz, Timothy F. Hom, Paul J. Wolters, Tushar J. Desai, Fernando Rock, Katerina Leftheris, David J. Morgans, Eve-Irene Lepist, Patrick Andre, Eric A. Lefebvre, Scott M. TurnerAdditional file 1. Materials and methods. Additional references. Fig. S1. (A) Viability of sentinel slices from lung tissue explants on Day 7. (B) Effect of PLN-74809 on Smad2 phosphorylation. (C) Dose titration of PLN-74809 on COL1A1 expression. Fig. S2. Dose titration of PLN-74809 on Col1a1 expression in PCLSs prepared from bleomycin-challenged mouse lung. Fig. S3. Antifibrotic effects of dual αvβ6/αvβ1 inhibition in the bleomycin mouse model. (A) Total lung hydroxyproline content and (B) 2H incorporation into lung hydroxyproline in sham-challenged mice and bleomycin-challenged mice treated with vehicle or PLN-74809. Fig. S4. Concentration required to decrease Col1a1 expression by 50% in PCLSs from acute bleomycin-challenged mouse lung. Table S1. Donor history for human lung samples. Table S2. Custom fibrosis gene panel. Table S3. TaqMan primers/probes.
